Senior Director, Integrated Planning & Analytics - Global Supply Chain

Who We Are

Bio Marin is a leading rare disease biotechnology company focused on genetically defined conditions.

Bio Marin is a leading rare disease biotechnology company focused on genetically defined conditions. Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options.

More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.

Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world‑class manufacturing capabilities. At the heart of Bio Marin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.

Bio Marin’s Technical Operations group is responsible for creating our drugs for use in clinical trials and for scaling production of those drugs for the commercial market. These engineers, technicians, scientists and support staff build and maintain Bio Marin’s cutting‑edge manufacturing processes and sites, provide quality assurance and quality control to ensure we meet regulatory standards, and procure the needed goods and services to support manufacturing and coordinating the worldwide movement of our drugs to patients.

Hybrid Position, requires 2 days onsite/ per week in San Rafael, CA (HQ)

The Senior Director, Integrated Planning & Analytics, leads enterprise planning across demand, supply, inventory, capacity, and financial objectives through Integrated Business Planning (IBP). This role drives profitable growth, operational agility, and patient‑centric outcomes across a global rare disease supply network by connecting decisions across Commercial, Clinical, Manufacturing, Quality, Regulatory, Medical Affairs, and Finance.

In a dynamic portfolio shaped by new indications, label expansions, named‑patient and compassionate use programs, and clinical‑to‑commercial transitions, this leader strengthens supply resilience, manages risk, and builds planning capabilities for long‑term growth.

As the global process owner for IBP, you will lead forward‑looking decision‑making across a 24–60‑month horizon, including long‑range capacity planning and modeling, inventory strategy, and data analytics that support reliable supply and patient access.

• IBP Process Ownership in a Rare Disease Environment
• Own the global IBP framework for rare disease planning, addressing demand variability, small batches, long lead times, and constrained capacity.
• Establish and maintain a consistent IBP cadence (Product Review, Demand Review, Supply Review, Integrated Reconciliation, Executive IBP).
• Own the S&OE (Sales & Operations Execution) process, ensuring near‑term demand, supply, and inventory decisions are aligned to the broader IBP framework and escalated appropriately.
• Embed patient‑centric planning principles into the IBP cycle (e.g., emergency orders, compassionate use, urgent clinical supply requests).
• Ensure seamless integration of clinical and commercial planning due to overlapping supply sources and shared manufacturing assets.
• Rare Disease Demand, Supply & Inventory Integration
• Oversee reconciliation of commercial, patient, named‑patient, early‑access, and clinical trial demand signals.
• Ensure supply plans reflect long cycle times, yield variability, cold‑chain requirements, and CMO dependencies.
• Lead Inventory Management to define inventory policies, targets, and positioning strategies that minimize expiry while guaranteeing immediate patient access for ultra‑low‑volume therapies.
• Lead risk‑based scenario planning…